BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 22622238)

  • 1. N-propionyl-4-S-cysteaminylphenol induces apoptosis in B16F1 cells and mediates tumor-specific T-cell immune responses in a mouse melanoma model.
    Ishii-Osai Y; Yamashita T; Tamura Y; Sato N; Ito A; Honda H; Wakamatsu K; Ito S; Nakayama E; Okura M; Jimbow K
    J Dermatol Sci; 2012 Jul; 67(1):51-60. PubMed ID: 22622238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of putative neo-antigen formation from N-propionyl-4-S-cysteaminylphenol, a tyrosinase substrate, in melanoma models.
    Ito S; Nishigaki A; Ishii-Osai Y; Ojika M; Wakamatsu K; Yamashita T; Tamura Y; Ito A; Honda H; Nakayama E; Jimbow K
    Biochem Pharmacol; 2012 Sep; 84(5):646-53. PubMed ID: 22728921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of artesunate on immune cells in ret-transgenic mouse melanoma model.
    Ramacher M; Umansky V; Efferth T
    Anticancer Drugs; 2009 Nov; 20(10):910-7. PubMed ID: 19745721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanoma-targeted chemo-thermo-immuno (CTI)-therapy using N-propionyl-4-S-cysteaminylphenol-magnetite nanoparticles elicits CTL response via heat shock protein-peptide complex release.
    Sato A; Tamura Y; Sato N; Yamashita T; Takada T; Sato M; Osai Y; Okura M; Ono I; Ito A; Honda H; Wakamatsu K; Ito S; Jimbow K
    Cancer Sci; 2010 Sep; 101(9):1939-46. PubMed ID: 20594194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-propionyl-cysteaminylphenol-magnetite conjugate (NPrCAP/M) is a nanoparticle for the targeted growth suppression of melanoma cells.
    Sato M; Yamashita T; Ohkura M; Osai Y; Sato A; Takada T; Matsusaka H; Ono I; Tamura Y; Sato N; Sasaki Y; Ito A; Honda H; Wakamatsu K; Ito S; Jimbow K
    J Invest Dermatol; 2009 Sep; 129(9):2233-41. PubMed ID: 19295615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A murine monoclonal antibody directed against the carboxyl-terminal domain of GRP78 suppresses melanoma growth in mice.
    de Ridder GG; Ray R; Pizzo SV
    Melanoma Res; 2012 Jun; 22(3):225-35. PubMed ID: 22495669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma.
    Niethammer AG; Xiang R; Ruehlmann JM; Lode HN; Dolman CS; Gillies SD; Reisfeld RA
    Cancer Res; 2001 Aug; 61(16):6178-84. PubMed ID: 11507070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulfur containing tyrosine analogs can cause selective melanocytotoxicity involving tyrosinase-mediated apoptosis.
    Minamitsuji Y; Toyofuku K; Sugiyama S; Yamada K; Jimbow K
    J Investig Dermatol Symp Proc; 1999 Sep; 4(2):130-6. PubMed ID: 10536987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity.
    Machlenkin A; Goldberger O; Tirosh B; Paz A; Volovitz I; Bar-Haim E; Lee SH; Vadai E; Tzehoval E; Eisenbach L
    Clin Cancer Res; 2005 Jul; 11(13):4955-61. PubMed ID: 16000595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B16 melanoma cell arrest in the mouse liver induces nitric oxide release and sinusoidal cytotoxicity: a natural hepatic defense against metastasis.
    Wang HH; McIntosh AR; Hasinoff BB; Rector ES; Ahmed N; Nance DM; Orr FW
    Cancer Res; 2000 Oct; 60(20):5862-9. PubMed ID: 11059784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The mechanism of anti-tumor immune response against mouse melanoma to xenogeneic vaccination].
    Luo F; Mao YQ; Kan B; He QM; Jiang Y; Peng F; Yang L; Tian L
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):757-60. PubMed ID: 15573746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Sulfur Containing Melanogenesis Substrate,
    Tamura Y; Ito A; Wakamatsu K; Torigoe T; Honda H; Ito S; Jimbow K
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982309
    [No Abstract]   [Full Text] [Related]  

  • 13. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic phosphoethanolamine a precursor of membrane phospholipids reduce tumor growth in mice bearing melanoma B16-F10 and in vitro induce apoptosis and arrest in G2/M phase.
    Ferreira AK; Meneguelo R; Marques FL; Radin A; Filho OM; Neto SC; Chierice GO; Maria DA
    Biomed Pharmacother; 2012 Oct; 66(7):541-8. PubMed ID: 22902646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8
    Yin W; Song Y; Liu Q; Wu Y; He R
    Immunology; 2017 Oct; 152(2):287-297. PubMed ID: 28556970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo anti-melanoma action of metformin.
    Janjetovic K; Harhaji-Trajkovic L; Misirkic-Marjanovic M; Vucicevic L; Stevanovic D; Zogovic N; Sumarac-Dumanovic M; Micic D; Trajkovic V
    Eur J Pharmacol; 2011 Oct; 668(3):373-82. PubMed ID: 21806981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenothiazines induce apoptosis in a B16 mouse melanoma cell line and attenuate in vivo melanoma tumor growth.
    Gil-Ad I; Shtaif B; Levkovitz Y; Nordenberg J; Taler M; Korov I; Weizman A
    Oncol Rep; 2006 Jan; 15(1):107-12. PubMed ID: 16328041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells.
    Wang CC; Chiang YM; Sung SC; Hsu YL; Chang JK; Kuo PL
    Cancer Lett; 2008 Jan; 259(1):82-98. PubMed ID: 18023967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
    Li Y; McGowan P; Hellström I; Hellström KE; Chen L
    J Immunol; 1994 Jul; 153(1):421-8. PubMed ID: 7515929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated restraint stress impairs the antitumor T cell response through its suppressive effect on Th1-type CD4+ T cells.
    Li T; Harada M; Tamada K; Abe K; Nomoto K
    Anticancer Res; 1997; 17(6D):4259-68. PubMed ID: 9494518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.